SCHEMBL20249366

SCHEMBL20249366

CC(C)(C)c1ccc(N2CCN(CC#N)CC2=O)cn1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.36
LMNA P02545 1/20 0.36
TSHR P16473 1/20 0.36
KMT2A Q03164 1/20 0.36
DRD3 P35462 2/20 0.35
KCNH2 Q12809 2/20 0.35
FNTA P49354 5/20 0.35
FNTB P49356 4/20 0.35
PGGT1B P53609 4/20 0.35
AR P10275 1/20 0.34
NRAS P01111 1/20 0.33
HRAS P01112 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
DRD2 P14416 1/20 0.32
PPARD Q03181 1/20 0.32
PPARA Q07869 1/20 0.32
HRH3 Q9Y5N1 1/20 0.32
CCR9 P51686 1/20 0.32
POLB P06746 1/20 0.32
WNT3A P56704 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20249319 0.84 DRD3 (0.35) LMNATSHRDRD3KCNH2FNTA
SCHEMBL20255395 0.84 DRD3 (0.50) ALDH1A1DRD3KCNH2FNTAFNTB
SCHEMBL20249300 0.82 PIK3CD (0.43) DRD3KCNH2L3MBTL1HRH3PARP1
SCHEMBL20249309 0.82 GAA (0.37) ALDH1A1LMNATSHRDRD3KCNH2
SCHEMBL20249326 0.82 AR (0.36) LMNATSHRDRD3KCNH2AR
SCHEMBL20249369 0.80 ALDH1A1 (0.38) ALDH1A1LMNATSHRDRD3KCNH2
SCHEMBL20249342 0.80 PARP1 (0.35) DRD3KCNH2DRD2PPARDPPARA
SCHEMBL20249115 0.78 SLC6A2 (0.42) LMNATSHRDRD3KCNH2L3MBTL1
SCHEMBL20249402 0.78 TLR8 (0.37) ALDH1A1LMNATSHRDRD3KCNH2
SCHEMBL20249390 0.78 IDH1 (0.33) HRH3TP53DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180161329-A1 PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF TEIJIN PHARMA LIMITED (JP) 2018-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180161329-A1 PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF CDK4, CDK6, CDK16 ALDH1A1 944/4885LMNA 3947/4885TSHR 2977/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.